Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024
Our study suggests that the safety profile of bedaquiline combined with moxifloxacin does not appear superior to that of bedaquiline combined with levofloxacin in terms of cardiac, hepatic, and neurological effects. Therefore, in the BPaLM regimen, considering the substitution of moxifloxacin with levofloxacin may be worthwhile if their efficacy is proven to be similar. Increased monitoring may be required for individuals under 45 years of age and male MDR-TB patients.
Authors
- Xiangping Xie
- Sheng Wei (ORCID: https://orcid.org/0009-0004-1343-7284)
- Sha Li (ORCID: https://orcid.org/0000-0002-1244-7542)
- Yanlang He
- Simin Tang (ORCID: https://orcid.org/0000-0002-5024-712X)
- Changping He
- Anping Zhang (ORCID: https://orcid.org/0009-0008-2658-0329)
Institutions
- Wannan Medical College (CN)
- Fujian University of Traditional Chinese Medicine (CN)
- The Central Hospital of Shaoyang (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.3389/fphar.2024.1491921
- Citations
- 4
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- National Natural Science Foundation of China